In several kinds of cancer, malignant cells display an excess of a specific type of surface receptor, which when stimulated causes unchecked growth of such cells (SN: 9/11/04, p. 164: Available to subscribers at An Exploitable Mutation: Defect might make some lung cancers treatable).
Scientists now report that a novel agent bottles up this so-called epidermal growth factor receptor and stalls the growth of cancer cells in a lab dish. The strong results have led the researchers to begin testing the new drug, called HKI-272, in people with lung cancer that has proved resistant to two existing anticancer drugs that target the same receptor, reports Daniel A. Haber of Massachusetts General Hospital Cancer Center in Charlestown.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.